Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation-Reference-Cited by-同舟云学术

Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation

Published:2020-10-29 Issue:3 Volume:97 Page:649-664
ISSN:1747-0277
Container-title:Chemical Biology & Drug Design
language:en
Short-container-title:Chem Biol Drug Des

Author:

Liu Juan¹²^ORCID,Zhang Yuan¹,Huang Honglin¹,Lei Xiaoyong¹,Tang Guotao¹,Cao Xuan¹,Peng Junmei¹

Affiliation:

1. Institute of Pharmacy and Pharmacology Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study University of South China Hengyang China

2. Pharmacy Department of Yiyang Central Hospital Yiyang China

Publisher

Wiley

Subject

Molecular Medicine,Biochemistry,Drug Discovery,Pharmacology,Organic Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cbdd.13801

Reference81 articles.

1. Allosteric inhibitors of Bcr-abl–dependent cell proliferation

2. High incidence of bcr‐abl kinase domain mutations and absence of mutations of the pdgfr and kit activation loops in cml patients with secondary resistance to imatinib;Al‐Ali H. K.;Hematol J,2004

3. Therapeutic options against bcr‐abl1 t315i‐positive chronic myelogenous leukemia;Alfonso Q.‐C.;Clinical Cancer Research,2008

4. Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1 35INS

5. Nocodazole, a microtubule depolymerising agent, induces apoptosis of chronic lymphocytic leukaemia cells associated with changes in Bcl-2 phosphorylation and expression

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs;ChemBioChem;2024-09-12

2. In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I;Molecules;2024-09-08

3. Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies;Journal of Advanced Research;2024-09

4. Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance;Cancers;2024-08-02

5. <i>De novo</i> design and virtual screening of potential Bcr-Abl tyrosine kinase inhibitors using deep learning and molecular modeling technologies;Doklady of the National Academy of Sciences of Belarus;2024-07-08